SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (1032)1/27/1998 5:30:00 AM
From: Henry Niman  Respond to of 2173
 
It's my understanding that LLY will begin combination trials in 1999 (Targretin with insulin, Rezulin, Metformin, or sulfanylureas). LGND announced the start European Phase II monotherapy trial last March and LLY is expected to begin the US Phase II trial in a few months. However, Targretin should be available at pharmacies sometime next year (NDA for oral treatment of CTCL is expected this year).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News